AMGEN AMG-451 Pro00115602 A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Amgen, Inc.
Start Date
May 24, 2024
End Date
April 4, 2029
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Amgen, Inc.
Start Date
May 24, 2024
End Date
April 4, 2029